Literature DB >> 15089813

The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Evan D Kharasch1, Christine Hoffer, Dale Whittington.   

Abstract

AIMS: There is considerable unexplained interindividual variability in the methadone dose-effect relationship. The efflux pump P-glycoprotein (P-gp) regulates brain access and intestinal absorption of many drugs. Evidence suggests that methadone is a P-gp substrate in vitro, and P-gp affects methadone analgesia in animals. However the role of P-gp in human methadone disposition and pharmacodynamics is unknown. This investigation tested the hypothesis that the intestinal absorption and pharmacodynamics of oral and intravenous methadone are greater after inhibition of intestinal and brain P-gp, using the P-gp inhibitor quinidine as an in vivo probe.
METHODS: Two randomized, double-blind, placebo-controlled, balanced crossover studies were conducted in healthy subjects. Pupil diameters and/or plasma concentrations of methadone and the primary metabolite EDDP were measured after 10 mg intravenous or oral methadone HCl, dosed 1 h after oral quinidine (600 mg) or placebo.
RESULTS: Quinidine did not alter the effects of intravenous methadone. Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)). Quinidine increased (P < 0.05) plasma methadone concentrations during the absorptive phase, decreased t(max) (2.4 +/- 0.7 vs 1.6 +/- 0.9 h (0.33, 1.2)), and increased peak miosis (3.2 +/- 1.5 vs 4.3 +/- 1.6 mm (-1.96, -0.19)) after oral methadone. The C(max) (55.6 +/- 10.3 vs 59.4 +/- 14.1 ng ml(-1) (-8.5, 0.65)) and AUC of methadone (298 +/- 46 vs 316 +/- 74 ng ml(-1) h (-54, 18)) were unchanged, as were the EDDP : methadone AUC ratios. Quinidine had no effect on the rate constant for transfer of methadone between plasma and effect compartment (k(e0)) (2.6 +/- 2.6 vs 2.5 +/- 1.4 h(-1) (-3.5, 4.2)).
CONCLUSIONS: Quinidine increased the plasma concentrations of oral methadone in the absorptive phase and the miosis caused by methadone, suggesting that intestinal P-gp affects oral methadone absorption and hence its clinical effects. Quinidine had no effect on methadone pharmacodynamics after intravenous administration, suggesting that if quinidine is an effective inhibitor of brain P-gp, then P-gp does not appear to be a determinant of the access of methadone to the brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15089813      PMCID: PMC1884496          DOI: 10.1111/j.1365-2125.2003.02053.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  59 in total

1.  Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain.

Authors:  C E Inturrisi; R K Portenoy; M B Max; W A Colburn; K M Foley
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

2.  Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation.

Authors:  J C Scott; D R Stanski
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

3.  The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice.

Authors:  R Xie; M Hammarlund-Udenaes; A G de Boer; E C de Lange
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington; Pam Sheffels
Journal:  Clin Pharmacol Ther       Date:  2003-12       Impact factor: 6.875

5.  Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine.

Authors:  A Hedman; B Angelin; A Arvidsson; R Dahlqvist; B Nilsson
Journal:  Clin Pharmacol Ther       Date:  1990-01       Impact factor: 6.875

6.  Profiles of opioid analgesia in humans after intravenous bolus administration: alfentanil, fentanyl and morphine compared on experimental pain.

Authors:  C R Chapman; H F Hill; L Saeger; J Gavrin
Journal:  Pain       Date:  1990-10       Impact factor: 6.961

7.  Effects of cyclosporine on anesthetic action.

Authors:  V N Cirella; C B Pantuck; Y J Lee; E J Pantuck
Journal:  Anesth Analg       Date:  1987-08       Impact factor: 5.108

8.  Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain.

Authors:  C E Inturrisi; W A Colburn; R F Kaiko; R W Houde; K M Foley
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

9.  Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.

Authors:  K Brøsen; F Davidsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

10.  EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil.

Authors:  J C Scott; K V Ponganis; D R Stanski
Journal:  Anesthesiology       Date:  1985-03       Impact factor: 7.892

View more
  22 in total

1.  P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception.

Authors:  Sarah M Brown; Scott D Campbell; Amanda Crafford; Karen J Regina; Michael J Holtzman; Evan D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  2012-06-27       Impact factor: 4.030

2.  Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.

Authors:  Tae-Eun Kim; Howard Lee; Kyoung Soo Lim; SeungHwan Lee; Seo-Hyun Yoon; Kyung-Mi Park; Hyesun Han; Sang-Goo Shin; In-Jin Jang; Kyung-Sang Yu; Joo-Youn Cho
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 3.  Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Authors:  Joseph D Ma; Shirley M Tsunoda; Joseph S Bertino; Meghana Trivedi; Keola K Beale; Anne N Nafziger
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

4.  The acute disposition of (R)- and (s)-methadone in brain and lung of sheep.

Authors:  David J R Foster; Richard N Upton; Andrew A Somogyi; Cliff Grant; Allison Martinez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Intraoperative methadone: rediscovery, reappraisal, and reinvigoration?

Authors:  Evan D Kharasch
Journal:  Anesth Analg       Date:  2011-01       Impact factor: 5.108

Review 6.  Pharmacogenomics of methadone: a narrative review of the literature.

Authors:  Senthil Packiasabapathy; Blessed W Aruldhas; Nicole Horn; Brian R Overholser; Sara K Quinney; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2020-07-24       Impact factor: 2.533

7.  A Conformationally Gated Model of Methadone and Loperamide Transport by P-Glycoprotein.

Authors:  Morgan E Gibbs; Laura A Wilt; Kaitlyn V Ledwitch; Arthur G Roberts
Journal:  J Pharm Sci       Date:  2018-02-28       Impact factor: 3.534

8.  Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study.

Authors:  Gavin Bart; Scott Lenz; Robert J Straka; Richard C Brundage
Journal:  Drug Alcohol Depend       Date:  2014-10-24       Impact factor: 4.492

9.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.

Authors:  E D Kharasch; P S Bedynek; S Park; D Whittington; A Walker; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

Review 10.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.